

In the Claims:

Please cancel claims 2-7, 10, 12-18, and 21-29 without prejudice to later prosecution. Please amend claims 1, 8, 9 and 19 as follows:

1. (Amended) A method of preparing a bispecific antibody comprising a first polypeptide and a second polypeptide, wherein

(a) the first polypeptide comprises a first multimerization domain that interacts with a multimerization domain of the second polypeptide,

(b) the first polypeptide and second polypeptide each comprise a different binding domain, a first binding domain comprising a first antibody variable heavy chain and a first antibody variable light chain, and a second binding domain comprising a second antibody variable heavy chain and a second antibody variable light chain, wherein the first and second variable light chains have at least 80% amino acid sequence identity, and

(c) the bispecific antibody is formed by the first variable light chain interacting with the first or second variable heavy chain in the first or second binding domain, and the second variable light chain interacting with the first or second variable heavy chain in the first or second binding domain, the method comprising the steps of:

(i) culturing a host cell comprising nucleic acid encoding the first polypeptide and second polypeptide, and the first and second variable light chain, wherein the culturing is such that the nucleic acid is expressed; and

(ii) recovering the bispecific antibody from the host cell culture.

8. (Amended) The method of claim 1 wherein the first polypeptide and second polypeptide each comprise an antibody constant domain.

9. (Amended) The method of claim 8 wherein the first polypeptide and second polypeptide each comprise an antibody constant domain from a C_H3 domain or from an IgG.

19. (Amended) A host cell comprising nucleic acid encoding a bispecific antibody comprising a first polypeptide and a second polypeptide, wherein

(a) the first polypeptide comprises a first multimerization domain that interacts with a multimerization domain of the second polypeptide,

(b) the first polypeptide and second polypeptide each comprise a different binding domain,

a first binding domain comprising a first antibody variable heavy chain and a first antibody variable light chain, and a second binding domain comprising a second antibody variable heavy chain and a second antibody variable light chain, wherein the first and second variable light chains have at least 80% amino acid sequence identity, and

(c) the bispecific antibody is formed by the first variable light chain interacting with the first or second variable heavy chain in the first or second binding domain, and the second variable light chain interacting with the first or second variable heavy chain in the first or second binding domain.